Page last updated: 2024-10-24

trachea cartilage development

Definition

Target type: biologicalprocess

The process whose specific outcome is the progression of the tracheal cartilage over time, from its formation to the mature structure. Cartilage is a connective tissue dominated by extracellular matrix containing collagen type II and large amounts of proteoglycan, particularly chondroitin sulfate. [GOC:dph]

Trachea cartilage development is a complex process that begins early in embryonic development and continues throughout childhood. It involves the coordinated interaction of multiple cell types, including mesenchymal cells, chondrocytes, and epithelial cells.

**1. Mesenchymal Condensation:** The process starts with the condensation of mesenchymal cells around the developing trachea. These cells express specific transcription factors that initiate chondrogenesis.

**2. Chondrocyte Differentiation:** Mesenchymal cells differentiate into chondrocytes, specialized cells responsible for producing cartilage matrix. These chondrocytes proliferate and secrete extracellular matrix components like collagen type II, aggrecan, and other proteoglycans.

**3. Cartilage Matrix Formation:** The secreted extracellular matrix forms a cartilaginous scaffold around the trachea, providing structural support and defining its shape. This matrix is composed of collagen fibers that provide tensile strength and proteoglycans that attract water, giving the cartilage its characteristic resilience.

**4. Tracheal Ring Formation:** The cartilaginous scaffold forms incomplete rings around the trachea, leaving open spaces to accommodate the esophagus. These rings ensure the trachea remains open and unobstructed for air passage.

**5. Growth and Maturation:** During childhood, the tracheal cartilages continue to grow and mature. This involves further deposition of cartilage matrix and the gradual replacement of hyaline cartilage with more rigid elastic cartilage in the posterior tracheal wall, providing flexibility during breathing.

**6. Epithelial Differentiation:** The trachea is lined by specialized epithelial cells that play a crucial role in protecting the respiratory tract from pathogens and debris. These cells differentiate into different types, including ciliated cells, goblet cells, and basal cells.

**7. Vascularization and Innervation:** Blood vessels and nerves penetrate the cartilage, providing nutrients and oxygen to the chondrocytes and regulating cartilage growth and repair.

**8. Regulation:** Trachea cartilage development is under the control of various signaling molecules, including growth factors, hormones, and transcription factors. These molecules regulate the proliferation, differentiation, and matrix deposition of chondrocytes.

The proper development of tracheal cartilage is essential for normal respiratory function. Defects in this process can lead to various respiratory problems, including tracheomalacia, a condition where the trachea collapses during breathing.'
"

Proteins (2)

ProteinDefinitionTaxonomy
Retinoic acid receptor gamma A retinoic acid receptor gamma that is encoded in the genome of human. [PRO:DNx, UniProtKB:P13631]Homo sapiens (human)
Retinoic acid receptor alphaA retinoic acid receptor alpha that is encoded in the genome of human. [PRO:DNx, UniProtKB:P10276]Homo sapiens (human)

Compounds (38)

CompoundDefinitionClassesRoles
am 5804-{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid : An amidobenzoic acid obtained by formal condensation of the carboxy group of (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)benzoic acid with the anilino group of 4-aminobenzoic acid. A selective RARalpha agonist.

Am 580: a selctive retinoic acid receptor (alpha) agonist; structure given in first source
amidobenzoic acid;
tetralins
antineoplastic agent;
retinoic acid receptor alpha/beta agonist
bms 961BMS 961: a retinoic acid receptor gamma agonist; no further info available 10/2006
lg 100268LG 100268: a retinoid X receptor (RXR) selective compound; structure given in first source
tazarotenetazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.

tazarotene: a topical acetylenic retinoid; a topical kerytolytic
acetylenic compound;
ethyl ester;
pyridines;
retinoid;
thiochromane
keratolytic drug;
prodrug;
teratogenic agent
adapaleneadapalene : A naphthoic acid that is CD437 in which the phenolic hydroxy group has been converted to its methyl ether.

Adapalene: A naphthalene derivative that has specificity for RETINOIC ACID RECEPTORS. It is used as a DERMATOLOGIC AGENT for the treatment of ACNE.
adamantanes;
monocarboxylic acid;
naphthoic acid
dermatologic drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
non-steroidal anti-inflammatory drug
bexarotenebenzoic acids;
naphthalenes;
retinoid
antineoplastic agent
tamibarotenetamibarotene : A dicarboxylic acid monoamide resulting from the condensation of one of the carboxy groups of terephthalic acid with the amino group of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-amine.

tamibarotene: has retinoid-binding activity
dicarboxylic acid monoamide;
retinoid;
tetralins
antineoplastic agent;
retinoic acid receptor alpha/beta agonist
4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl)benzoic acid
cd 437CD 437: selective for retinoic acid receptors gamma

CD437 : A naphthoic acid that is 6-phenylnaphthylene-2-carboxyic acid in which the phenyl substituent has been substituted at positions 3 and 4 by adamant-1-yl and hydroxy groups, respectively. It acts as a selective agonist of retinoic acid receptor (RAR)gamma and induces cell cycle arrest and apoptosis in various cancer cells.
adamantanes;
monocarboxylic acid;
naphthoic acid;
phenols
apoptosis inducer;
retinoic acid receptor gamma agonist
6-(1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-naphthyl)-2-naphthalenecarboxylic acid6-(1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-naphthyl)-2-naphthalenecarboxylic acid: reverses keratinization process in hamster tracheal organ culture; inhibits induction of ornithine decarboxylase; structure & RN given in first source; RN not in Chemline 12/5/83
cd 2019CD 2019: a retinoic acid receptor beta2 agonist; structure given in first source
agn 193109AGN 193109: structure given in first source
tretinoinall-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.

retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).

Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).
retinoic acid;
vitamin A
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule
bms 195614BMS 195614 : A carboxamide resulting from the formal condensation of the carboxy group of 5,5-dimethyl-8-(quinolin-3-yl)-5,6-dihydronaphthalene-2-carboxylic acid with the amino group of p-aminobenzoic acid. It is a neutral retinoic acid receptor (RAR) alpha-selective antagonist (Ki = 2.5 nM). It displays no significant effect on nuclear receptor corepressor (NCoR) binding; moderately decreases SMRT binding to RAR. It antagonizes agonist-induced coactivator (CoA) recruitment.benzoic acids;
quinolines;
secondary carboxamide
retinoic acid receptor alpha antagonist
bms 961
alitretinoinAlitretinoin: A retinoid that is used for the treatment of chronic hand ECZEMA unresponsive to topical CORTICOSTEROIDS. It is also used to treat cutaneous lesions associated with AIDS-related KAPOSI SARCOMA.retinoic acidantineoplastic agent;
keratolytic drug;
metabolite;
retinoid X receptor agonist
ac 556494'-octyl-4-biphenylcarboxylic acid: an RAR beta2 agonist; structure in first sourcebiphenyls;
carboxybiphenyl
sr 11217SR 11217: structure given in first source
clothiapinemaleate salt
lg 100567ALRT 1550: ALRT1550 is (2E,4E,6E)-isomer; LG100567 is (2E,4E,6Z)-isomer; structure given in first source
fenretinide4-hydroxyphenyl retinamide : A retinoid obtained by formal condensation of the carboxy group of all-trans retinoic acid and the anilino group of 4-hydroxyaniline. Synthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids.

Fenretinide: A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.
monocarboxylic acid amide;
retinoid
antineoplastic agent;
antioxidant
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid: RN refers to (E)-isomer; structure given in first source

arotinoid acid : A retinoid that consists of benzoic acid substituted at position 4 by a 2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-en-1-yl group. It is a synthetic retinoid that acts as a selective agonist for the retinoic acid receptors (RAR).
benzoic acids;
naphthalenes;
retinoid
antineoplastic agent;
retinoic acid receptor agonist;
teratogenic agent
agn 191659AGN 191659: a retinoid x receptor pan-agonist; structure in first source
agn 191701AGN 191701: retinoid X receptors agonist; RN refers to (E)-isomer; structure given in first source
pregna-4,17-diene-3,16-dionepregna-4,17-diene-3,16-dione: steroid from guggulu extract; RN & N1 from C1 Form index; RN given refers to cpd without isomeric designation; structure in first source; antagonist of farnesoid X receptor3-hydroxy steroidandrogen
agn 190121
lg100754LG 100754: retinoic acid receptors antagonist & agonist; a mixed function retinoid whose activity is dimer-selective; structure given in first source
lg 1506
nrx 194204IRX4204: retinoid X receptor (RXR) agonist; structure in first source
agn 194204AGN 194204: a retinoid X receptor ligand; structure in first source
bms453BMS 189453: structure in first source

BMS-453 : A member of the class of dihydronaphthalenes that is 1,2-dihydronaphthalene which is substituted at positions 1, 1, 4, and 6 by methyl, methyl, phenyl, and 2-(p-carboxyphenyl)vinyl groups, respectively (the E isomer). It is a potent retinoic acid receptor gamma (RARbeta) agonist that acts as an antagonist against RARalpha and RARgamma.
benzoic acids;
dihydronaphthalenes;
stilbenoid
retinoic acid receptor alpha antagonist;
retinoic acid receptor beta agonist;
retinoic acid receptor gamma antagonist;
teratogenic agent
hx 630HX 630: a retinoid X receptor ligand that functions as both an RAR synergist and peroxisome proliferator-activated receptor gamma synergist; structure in first source
bms 204493BMS-493 : A member of the class of dihydronaphthalenes that is 1,2-dihydronaphthalene which is substituted at positions 1, 1, 4, and 6 by methyl, methyl, phenylethynyl, and 2-(p-carboxyphenyl)vinyl groups, respectively (the E isomer).acetylenic compound;
benzoic acids;
dihydronaphthalenes;
stilbenoid
retinoic acid receptor antagonist
sr 11302SR 11302: structure given in first source

SR11302 : A retinoid that is all-trans-retinoic acid in which the methyl group at position 9 is replaced by a 4-methylphenyl group. It is an inhibitor of activator protein-1 which exhibits antitumour effects in vivo.
alpha,beta-unsaturated monocarboxylic acid;
retinoid;
toluenes
antineoplastic agent;
AP-1 antagonist
cd 666
agn 190205AGN 190205: inhibits vascular smooth muscle cell proliferation; structure in first source
le 135LE 135: structure given in first sourcedibenzodiazepine
ac 261066